This would contravene the fact that EU legislation applies to all funds which invest in OTC instruments. Given this possibly negative effect on the internal market and the risks inherent in OTC instruments, the Commission cannot accept Amendments Nos 12, 15, 37, 38, 39, 43, 46 and 48 and parts of Amendments Nos 17, 36 and 45 which pertain to OTC instruments.
Au vu de cette potentielle conséquence négative pour le marché intérieur et des risques intrinsèques des instruments OTC, la Commission ne peut accepter les amendements 12, 15, 37, 38, 39, 43, 46 et 48 et les parties des amendements 17, 36 et 45 qui se rapportent aux instruments OTC.